<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943536</url>
  </required_header>
  <id_info>
    <org_study_id>CP-002</org_study_id>
    <nct_id>NCT04943536</nct_id>
  </id_info>
  <brief_title>Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer</brief_title>
  <acronym>Biolen + RT</acronym>
  <official_title>Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alessa Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alessa Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be undertaken to evaluate the feasibility of replacing systemic Androgen&#xD;
      Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in&#xD;
      patients in whom ADT + radiation therapy is indicated for the treatment of localized prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-center, single-arm feasibility study. Up to 20&#xD;
      participants will be recruited to assess the safety and patient tolerance of Biolen for the&#xD;
      localized delivery of bicalutamide into the prostate when delivered with radiotherapy.&#xD;
&#xD;
      At baseline, patients will undergo multiparametric MRI of the prostate. Study participants&#xD;
      will have placement of the drug eluting Biolen implants. At the 8 week timepoint,&#xD;
      participants will undergo repeat multiparametric MRI.&#xD;
&#xD;
      Participants will receive standard of care radiation therapy on weeks 9-11 and will be&#xD;
      followed through 2 years post radiation. A third and fourth multiparametric MRI will be&#xD;
      performed at 6 and 24 months after completion of radiation. Clinical labs and correlative&#xD;
      sample collection and patient quality of life questionnaires will be administered at&#xD;
      follow-up visits. Following completion of follow-up or removal from protocol, patients may be&#xD;
      offered enrollment on long-term follow up protocols.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of replacing systemic androgen tx with targeted local delivery</measure>
    <time_frame>27 months</time_frame>
    <description>Ability to successfully implant the prostate with Biolen and a lack of implant toxicity that interferes with the capacity to complete intended radiation therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>through 27 months</time_frame>
    <description>toxicity of localized delivery of bicalutamide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI changes</measure>
    <time_frame>baseline versus 8 weeks post biolen implantation and 6 months post RT</time_frame>
    <description>prostate and tumor volume changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical progression free survival</measure>
    <time_frame>24 months post RT</time_frame>
    <description>rate of biochemical progression free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Biolen+Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Localized single delivery of the Biolen implant (polymer + bicalutamide) with radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
    <description>localized anti-androgen therapy</description>
    <arm_group_label>Biolen+Radiation Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic body radiation therapy</intervention_name>
    <description>localized radiation therapy</description>
    <arm_group_label>Biolen+Radiation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with biopsy proven localized prostate cancer in whom prostate radiation and&#xD;
             ADT is appropriate therapy (such as Intermediate Risk localized prostate cancer)&#xD;
&#xD;
          -  Patients must have at least 1 MRI detected; biopsy proven prostate cancer.&#xD;
&#xD;
          -  Patients diagnosed as one of the following:&#xD;
&#xD;
               1. National Comprehensive Cancer Network (NCCN) intermediate risk prostate cancer,&#xD;
                  OR&#xD;
&#xD;
               2. NCCN high risk prostate cancer due to Gleason Grade 4 or 5 AND refuses to receive&#xD;
                  systemic ADT, OR&#xD;
&#xD;
               3. NCCN high risk prostate cancer due to Prostate Specific Antigen (PSA) &gt; 20 AND&#xD;
                  refuses to receive systemic ADT.&#xD;
&#xD;
          -  Age &gt;18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NCCN high risk patients eligible for treatment with systemic ADT who do not refuse&#xD;
             systemic ADT.&#xD;
&#xD;
          -  Patients receiving prior radiotherapy or surgery for prostate cancer.&#xD;
&#xD;
          -  Patients receiving prior or ongoing ADT.&#xD;
&#xD;
          -  Study participant unwilling or unable to undergo MRI, including patients with&#xD;
             contra-indications to MRI, such as cardiac pacemakers, non-compatible intracranial&#xD;
             vascular clips, etc.&#xD;
&#xD;
          -  Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months&#xD;
             of screening or total use within the last two years prior to screening of &gt; 3 months.&#xD;
&#xD;
          -  Prostate volume more than 80 cc at prior MRI imaging.&#xD;
&#xD;
          -  International Prostate Symptom Score â‰¥ 20.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Citrin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Citrin, MD</last_name>
    <phone>301-496-5457</phone>
    <email>citrind@mail.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Theresa Cooley-Zgela, RN</last_name>
    <phone>240-764-6207</phone>
    <email>theresa.cooleyzgela@nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20894</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Deborah Citrin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

